ロード中...
Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells
BACKGROUND: Due to the frequent dysregulation of the PI3K/AKT/mTOR signaling pathway, mTOR represents a suitable therapeutic target in hepatocellular carcinoma (HCC). However, emerging data from clinical trials of HCC patients indicate that mTOR inhibition by RAD001 (Everolimus) alone has only moder...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2012
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3545733/ https://ncbi.nlm.nih.gov/pubmed/23167739 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-11-85 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|